Clinical Efficacy Evaluation Of SGLT2 Inhibitors In HFpEF Patients With T2DM

Objective: To investigate the clinical efficacy of SGLT2 inhibitor in HFp EF combined with T2 DM by retrospective analysis of clinical data of patients with T2 DM.Method: A total of 84 T2 DM patients with HFp EF who were admitted to the Department of Cardiology in our hospital from December 2020 to June 2022 were selected and divided into the conventional group(41 cases)and the treatment group(43cases)according to whether the patients used SGLT2 inhibitors.The conventional group only received conventional anti-heart failure treatment.The treatment group was additionally treated with the SGLT2 inhibitor canagliflozin 100 mg once a day.Before comparing the two groups of patients,After 12 weeks of treatment,N-terminal probrain natriuretic peptide(NT-pro BNP),6-minute walking test(6MWT),left ventricular end-systolic diameter(LVDS),left ventricular end-diastolic diameter(LVDD),left ventricular short-axis systolic rate(FS),left ventricular injection blood pressure(JP),mean arterial pressure(PM),total impedance(RTM),myocardial oxygen consumption(CMO),coronary ischemia threshold(CMR),flow smoothness(CTN),systolic blood pressure and diastolic blood pressure.To analyze the clinical efficacy of SGLT2 inhibitor in HFp EF patients with T2 DM.Results: In this study,a total of 84 patients met the criteria,including 41 in the control group and 43 in the treatment group.Comparison of the two groups:(1)In baseline data,there were no significant differences in body mass index(BMI),age,sex,cardiac function grade,proportion of underlying diseases and proportion of residual drugs(P>0.05).(2)NT-pro BNP in the treatment group was lower than that in the control group,P<0.05,and the difference was statistically significant.6MWT was higher than that of control group,P<0.05.(3)LVDS and LVDD in the treatment group were lower than those in the control group,P<0.05.There was no statistical difference between FS and control group(P>0.05).(4)After treatment,PM,RTM and CMO in the treatment group were lower than those in the control group(P<0.05),and CMR and CTN were higher than those in the control group(P<0.05).There was no statistical difference between JP and control group(P>0.05).(5)After treatment,the systolic blood pressure in the treatment group was lower than that in the control group,P<0.05.The effect on diastolic blood pressure is not obvious between the two groups(P>0.05).Conclusions: Compared with conventional treatment,combined treatment with SGLT2 inhibitor(canagliflozin)can further improve the cardiac function of HFp EF patients with T2 DM,reduce mean arterial pressure,total impedance,myocardial oxygen consumption,and improve coronary microcirculation.At the same time,systolic blood pressure can be reduced,but diastolic blood pressure has no obvious effect.